#Denmark #Nordic Bioscience #Herlev #nordicEndotrophin #biomarker test

Nordic Bioscience Unveils nordicEndotrophin Test

Nordic Bioscience has officially introduced their latest innovation, the nordicEndotrophin™, a fully automated high-precision test that selectively quantifies the intact 77-amino acid Endotrophin signaling hormone. Developed and validated in their CAP/CLIA-certified laboratory in Herlev, Denmark, this groundbreaking biomarker assay has demonstrated its prognostic utility in fibrosis and cancer studies.

This new test complements the company’s existing product line, featuring the nordicPRO-C6™ and nordicPRO-C3™, both proprietary versions of the FDA-supported PRO-C6 and CE-marked PRO-C3 assays. Together, these products offer a comprehensive solution for assessing the fibro-inflammatory axis in chronic diseases, including cardiovascular, metabolic, and renal conditions. Following the recent launch of PRO-C3 on Roche’s IVD platforms, the Endotrophin assay strengthens risk stratification and pharmacodynamic monitoring capabilities for healthcare professionals.

Endotrophin was first identified in 2012 as a collagen-derived hormone released from type VI collagen, crucial for fibroblast activation and organ fibrosis. Such inflammatory processes are attributed to approximately 40% of deaths in Western countries, where conditions like obesity exacerbate the activation of fibroblasts in key organs like the liver, kidneys, and heart. Research indicates that patients with a 100% increase in circulating Endotrophin levels face a doubled mortality risk due to various chronic ailments.

By quantifying Endotrophin, researchers can correlate wound healing and fibrosis progression with patient outcomes, supporting precision medicine approaches that target this harmful hormone pharmacodynamically. The innovative design of the nordicEndotrophin™ specifically assesses the intact 77-amino acid hormone, offering additional risk stratification and prognostic potential, enhancing the fibrosis-related pharmacodynamic insights provided by the nordicPRO-C6™.

“Endotrophin is a significant prognostic biomarker poised to gain prominence,” remarked CEO Dr. Morten Karsdal. “In a study involving HFpEF patients, Endotrophin and PRO-C6 significantly outperformed NT-proBNP in terms of mortality and hospitalization risk. Together with PRO-C3, quantifying this fibro-inflammatory hormone will enhance patient stratification and treatment monitoring in obesity and fibrotic disorders.”

The nordicEndotrophin™ sandwich assay is provided on fully automated, high-throughput platforms, promoting efficiency and accuracy in fibro-inflammation profiling. Clients considering nordicEndotrophin™ are encouraged to concurrently measure the nordicPRO-C3™ and nordicPRO-C6™ for a streamlined risk stratification process. Collectively, these assays facilitate precise risk stratification, dosing decisions, patient enrichment, and treatment monitoring in studies targeting fibrotic conditions and oncology initiatives.

About Nordic Bioscience

Nordic Bioscience, headquartered in Herlev, Denmark, is a pioneering biomarker company focused on developing innovative biomarkers using unique neoepitope technology. By combining their expertise in biomarker development with clinical and preclinical research, Nordic Bioscience aims to deliver rapid, objective decision-making tools for clinical trial composition and development, ultimately benefiting patients in diagnostic settings. For more information, visit Nordic Bioscience's website.